Paul A. Marks
Impact in
- Molecular Biology top 0.1%
- Histone Deacetylase Inhibitors Research
- Protein Degradation and Inhibitors
- Epigenetics and DNA Methylation
- Ubiquitin and proteasome pathways
- Hematology top 0.2%
Papers in
-
- Histone Deacetylase Inhibitors Research 57
- Protein Degradation and Inhibitors 30
- Epigenetics and DNA Methylation 17
- Ubiquitin and proteasome pathways 14
- Physiology 48
- Erythrocyte Function and Pathophysiology 41
- Co-authors
- Richard A. Rifkind (68 shared papers)Victoria M. Richon (36 shared papers)Ronald Breslow (9 shared papers)Milos Dokmanovic (5 shared papers)William Kevin Kelly (7 shared papers)Thomas A. Miller (3 shared papers)Todd W. Sandhoff (1 shared paper)Xuejun Jiang (4 shared papers)
- Journals
- Proceedings of the National Academy of Sciences (33 papers)Journal of Clinical Investigation (15 papers)Annals of the New York Academy of Sciences (11 papers)Journal of Biological Chemistry (10 papers)Nature (8 papers)
- Partner nations
- United StatesCanadaUnited Kingdom
In The Last Decade
Paul A. Marks
198 papers receiving 21.6k citations
Paul A. Marks's Hit Papers
Peers
Comparison fields: 5 of 173
- Molecular Biology 17.2k
- Hematology 2.0k
- Genetics 1.7k
- Oncology 3.9k
- Physiology 526
Countries citing papers authored by Paul A. Marks
This map shows the geographic impact of Paul A. Marks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul A. Marks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul A. Marks more than expected).
Fields of papers citing papers by Paul A. Marks
This network shows the impact of papers produced by Paul A. Marks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul A. Marks. The network helps show where Paul A. Marks may publish in the future.
Co-authors
The 25 scholars most cited alongside Paul A. Marks, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 204 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Histone deacetylases and cancer: causes and therapies Hit paper breakdown → | 2001 | 1560 |
| 2 | Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors Hit paper breakdown → | 1999 | 1425 |
| 3 | Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug Hit paper breakdown → | 2007 | 974 |
| 4 | Histone Deacetylase Inhibitors: Overview and Perspectives Hit paper breakdown → | 2007 | 938 |
| 5 | Histone deacetylase inhibitor selectively induces p21 WAF1 expression and gene-associated histone acetylation Hit paper breakdown → | 2000 | 932 |
| 6 | A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases Hit paper breakdown → | 1998 | 758 |
| 7 | Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer Hit paper breakdown → | 2005 | 741 |
| 8 | Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease Hit paper breakdown → | 2003 | 669 |
| 9 | Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Hit paper breakdown → | 2003 | 524 |
| 10 | Apoptotic and autophagic cell death induced by histone deacetylase inhibitors Hit paper breakdown → | 2004 | 523 |
| 11 | 2001 | 460 | |
| 12 | 2003 | 445 | |
| 13 | 2002 | 435 | |
| 14 | 2005 | 430 | |
| 15 | 2005 | 405 | |
| 16 | 2004 | 367 | |
| 17 | 2005 | 345 | |
| 18 | Differentiation of normal and neoplastic hematopoietic cells | 1978 | 325 |
| 19 | The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. | 2001 | 304 |
| 20 | 2010 | 293 |
About Paul A. Marks
Paul A. Marks is a scholar working on Molecular Biology, Physiology, Genetics, Hematology and Oncology, having authored 204 papers that have together received 22.7k indexed citations. Recurring topics across this work include Histone Deacetylase Inhibitors Research (57 papers), Hemoglobinopathies and Related Disorders (46 papers), Erythrocyte Function and Pathophysiology (41 papers), Protein Degradation and Inhibitors (30 papers), Epigenetics and DNA Methylation (17 papers), Ubiquitin and proteasome pathways (14 papers), Neonatal Health and Biochemistry (14 papers) and Peptidase Inhibition and Analysis (14 papers). The work is most often cited by research in Molecular Biology (17.2k citations), Hematology (2.0k citations), Genetics (1.7k citations), Oncology (3.9k citations) and Physiology (526 citations). Paul A. Marks has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Richard A. Rifkind, Victoria M. Richon, Ronald Breslow, Milos Dokmanovic, William Kevin Kelly, Thomas A. Miller, Todd W. Sandhoff, Xuejun Jiang, Xianbo Zhou and Lang Ngo. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation, Annals of the New York Academy of Sciences, Journal of Biological Chemistry and Nature.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.